Interferon-beta1a for the treatment of multiple sclerosis (Q31106233)

28 June 2017

1 reference

title

Interferon-beta1a for the treatment of multiple sclerosis (English)

1 reference

28 June 2017

0 references

Marinella Clerico

1

1 reference

28 June 2017

Giulia Contessa

series ordinal

2

1 reference

28 June 2017

Luca Durelli

series ordinal

3

1 reference

28 June 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Biological Therapy

28 June 2017

1 reference

28 June 2017

7

1 reference

28 June 2017

535-542

1 reference

28 June 2017

4

1 reference

Defining the clinical course of multiple sclerosis: Results of an international survey

28 June 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Interferon-beta induced remission in a hairy cell leukemia patient resistant to interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Clinical effect of interferon in malignant brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

HLA class I heavy-chain gene promoter elements mediating synergy between tumor necrosis factor and interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Beta-interferon and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Multiple sclerosis: side effects of interferon beta therapy and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

21 January 2018

Adherence to Medication

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Interferons in relapsing remitting multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Ingested (oral) IFN-alpha represses TNF-alpha mRNA in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.535

21 January 2018

Identifiers

DOI

10.1517/14712598.7.4.535

1 reference

28 June 2017

1 reference